Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof

Abstract

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

1 : A method of inhibiting immune cell proliferation, the method comprising administering a therapeutically effective amount of a composition containing sialyllactose or a pharmaceutically acceptable salt thereof as an active ingredient to a patient in need of treatment. 
     
     
         2 : The method of  claim 1 , wherein the sialyllactose is 3′-sialyllactose or 6′-sialyllactose. 
     
     
         3 : The method of  claim 2 , wherein the salt of 3′-sialyllactose has a structure of the following Formula 1: 
       
         
           
           
               
               
           
         
       
     
     
         4 : The method of  claim 2 , wherein the salt of 6′-sialyllactose has a structure of the following Formula 2: 
       
         
           
           
               
               
           
         
       
     
     
         5 : The method of  claim 1 , wherein the method has prophylactic or therapeutic effects on atopic dermatitis or rheumatoid arthritis. 
     
     
         6 : The method of  claim 1 , wherein the method has one or more of the following characteristics of:
 1) increasing expression of type II collagen (Col2a1);   2) decreasing expression of matrix metalloproteinase3 (Mmp3) or matrix metalloproteinase13 (Mmp13);   3) increasing Sox-9 activity; and   4) increasing inactivation of p-ERK.   
     
     
         7 : The method of  claim 1 , wherein the method has one or more of the following characteristics of:
 1) decreasing expression of chemokines;   2) decreasing expression of pro-inflammatory cytokines;   3) decreasing production of inflammatory mediators;   4) decreasing expression of COX2; and   5) decreasing production of PEG 2 .   
     
     
         8 : The method of  claim 1 , wherein the method has one or more of the following characteristics of:
 1) inhibiting synovial hyperplasia; and   2) inhibiting infiltration of mononuclear cells.   
     
     
         9 : The method of  claim 1 , further comprising a pharmaceutically acceptable carrier, excipient, or diluent. 
     
     
         10 - 20 . (canceled)